Granules India receives US FDA approval for gabapentin tablets

Granules India receives US FDA approval for gabapentin tablets

By, Admin 30 March 2023

Granules India Limited, a vertically integrated fast growing Indian pharmaceutical company, announced that the US Food & Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for gabapentin tablets USP, 600 mg and 800 mg. It is bioequivalent to the reference listed drug product (RLD), Neurontin tablets, 600 mg and 800 mg, of Viatris Specialty LLC. The current annual US market for gabapentin tablets is approximately $145 million, according to MAT Jan 2023, IQVIA/IMS Health. Gabapentin tablets are indicated for management of postherpetic neuralgia in adults; and as an adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and paediatric patients 3 years and older with epilepsy. Granules now has a total of 55 ANDA approvals from US FDA (53 final approvals and 2 tentative approvals). Granules India Limited has consistently achieved manufacturing success, set new standards of quality, and expanded its presence across the world. Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered in Hyderabad with best-in-class facilities and a commitment to operational excellence, quality, and customer service.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!